10-K: MariMed 2025 Annual Report: Growth Amidst Regulatory Shifts

MariMed Inc. reports a 1.3% revenue increase in 2025, driven by wholesale growth and strategic acquisitions, while navigating evolving cannabis regulations and federal tax challenges.

Summary

• MariMed Inc. is a multi-state cannabis operator (MSO) headquartered in Norwood, Massachusetts, focused on seed-to-sale cultivation, production, and dispensing of medicinal and adult-use cannabis.
• The company's strategic growth plan, "Expand the Brand," aims to increase product brand revenue and retail store revenue through enhanced capabilities, new product launches, broader distribution, and dispensary footprint expansion.
• MariMed holds 33 cannabis licenses across six states, including Illinois, Maryland, Massachusetts, Delaware, and Ohio, with pending operations in Pennsylvania and New York.
• Total revenue increased by 1.3% to $159.8 million in 2025, up from $157.7 million in 2024, primarily driven by a 10.6% increase in wholesale revenue.
• Gross profit decreased by 7.6% to $57.9 million in 2025 from $62.6 million in 2024, with the gross margin declining from 39.7% to 36.2%.
• The company reported a net loss of $14.5 million in 2025, an increase from a net loss of $12.4 million in 2024.
• Adjusted EBITDA decreased by 12.8% to $16.9 million in 2025 from $19.3 million in 2024.
• MariMed completed the acquisition of First State Compassion Center (FSC) in Delaware in March 2025, integrating its operations into the dual medical and adult-use market.
• In February 2026, the company restructured its Series B Convertible Preferred Stock, extinguishing a $14.2 million obligation and issuing $8.0 million in new promissory notes and new Series B Preferred Stock with a $6.725 million liquidation preference.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed report with concerning declines in profitability metrics (net loss, gross profit, Adjusted EBITDA) despite modest revenue growth. The ongoing federal illegality and tax liens present significant headwinds, though the Series B restructuring addresses a near-term obligation.

Positives

• Total revenue increased by 1.3% to $159.8 million in 2025, demonstrating continued top-line growth.
• Wholesale revenue grew significantly by 10.6% ($6.7 million increase) in 2025, driven by strong performance in Illinois, Maryland, and the inclusion of Delaware operations.
• Successfully completed the acquisition of First State Compassion Center (FSC) in Delaware in March 2025, expanding the company's footprint into a new adult-use market.
• Delaware commenced adult-use cannabis sales in August 2025, and Ohio expanded to adult-use sales in June 2024, opening new market opportunities for MariMed.
• Continued investment in the development and expansion of its proprietary brand portfolio, including new product formats and formulations, supported by ongoing R&D.
• Refined wholesale and retail strategies focused on improving operational efficiency, enhancing customer experience, and increasing brand penetration in core markets.
• The management team is highly experienced, with several executive members having a decade or more of experience in the cannabis industry.
• Successfully increased retail transactions and market share of core products through upgraded marketing efforts and customer loyalty programs.
• The potential rescheduling of cannabis to Schedule III under the CSA could eliminate IRS Tax Code 280E, saving the company several million dollars annually in federal taxes and increasing consumer trust.

Negatives

• Net loss increased to $14.5 million in 2025 from $12.4 million in 2024, indicating a decline in overall profitability.
• Gross profit decreased by 7.6% to $57.9 million in 2025, and gross margin declined from 39.7% in 2024 to 36.2% in 2025.
• Retail revenue decreased by 2.5% ($2.3 million) in 2025, primarily due to lower sales in Illinois dispensaries.
• Adjusted EBITDA decreased by 12.8% to $16.9 million in 2025 from $19.3 million in 2024.
• Other revenue decreased significantly by 65.4% ($2.3 million) in 2025, mainly due to the cessation of management fees and rental income post-FSC acquisition.
• Cost of revenue increased by 7.2% in 2025, primarily due to higher employee-related costs and facilities expenses associated with acquisitions and expanded operations.
• Recorded $1.6 million of bad debt expense in 2025, including a $1.5 million reserve for amounts due from two credit card service providers.
• Experienced a $0.7 million loss from a cybersecurity incident in September 2023 due to a fraudulent email, highlighting security vulnerabilities.
• Incurred a $0.8 million loss on the strategic exit from Missouri operations in October 2025.
• The IRS filed liens against MariMed and its subsidiary FSC for approximately $6 million and $1.3 million, respectively, for 2023 income taxes, which are currently being disputed.
• An accrued liability of $2.0 million for electrical work performed between 2017-2023 at New Bedford and Middleborough properties remains on the balance sheet, with payment terms still under negotiation.

Risks

• Cannabis remains illegal under United States federal law, posing significant risks of fines, penalties, administrative sanctions, criminal charges, and potential cessation of business activities.
• The enforcement of applicable United States federal laws could materially adversely affect the company's reputation, ability to hold licenses, financial position, operating results, profitability, liquidity, or the market price of its shares.
• Uncertainty surrounds the timing, scope, and outcome of potential changes to cannabis and hemp-related federal regulations, including the rescheduling of cannabis.
• IRS Tax Code 280E prohibits cannabis businesses from deducting ordinary business expenses, leading to substantially higher effective tax rates and potentially operating at a loss after taxes.
• Potential involvement of the U.S. Food and Drug Administration (FDA) in industry regulation could impose new costs, requirements, and prohibitions.
• The cannabis industry is relatively new and volatile, with state regulations subject to frequent changes that can impose unforeseen compliance costs.
• Limited clinical trials on cannabis benefits mean future research could result in negative conclusions, adversely affecting social acceptance or demand for products.
• Competition from adjacent adult-use segments, such as hemp-derived Delta 9 cannabinoids and psilocybin mushrooms, which may operate under less stringent regulations.
• Failure to comply fully with applicable regulatory requirements in all jurisdictions could lead to sanctions, license revocation, or increased compliance costs.
• Cannabis businesses may lack access to United States bankruptcy protections, making it difficult for lenders to recoup investments.
• Property owned by participants in the cannabis industry could be subject to civil asset forfeiture by law enforcement due to federal illegality.
• Future growth is dependent on additional states legalizing cannabis, which is not assured and can encounter setbacks.
• The strategic growth plan is subject to regulatory hurdles, delays, and uncertainties in obtaining new licenses or transferring existing ones.
• Increasing competition from other Multi-State Operators (MSOs) and Single State Operators may lead to declining sales or downward pressure on retail prices.
• Limits on the number of cannabis licenses one entity may own in certain states can restrict organic growth or market share increase.
• Difficulty obtaining or maintaining necessary permits and authorizations could restrict the ability to operate.
• Limited access to banking services due to federal illegality may make it difficult to operate in certain markets.
• Constraints on marketing products under varying state laws limit the consistency and scale of consumer branding and product education efforts.
• Inherent risks of product liability claims, regulatory action, and litigation if products are alleged to cause harm, are tampered with, or contaminated.
• Product recalls due to defects, harmful side effects, or inadequate labeling could result in significant expenses, lost sales, and reputational damage.
• Risks related to growing an agricultural product, such as loss due to infestation by insects, plant diseases, or similar agricultural risks.
• Onerous and costly environmental regulations could adversely affect operations.
• Covenants and restrictions in existing debt agreements may limit options for additional financing and impact cash flow.
• Anti-Money Laundering Laws in the United States may limit access to funds from banks and other financial institutions.
• Failure to hire and retain key personnel, or the loss of executive officers, could negatively impact business objectives and future growth.
• Risks related to acquiring or merging with companies or technologies, including integration challenges, diversion of management time, and potential write-offs.
• Cybersecurity risks, including data breaches, cyberattacks, and system disruptions, could lead to operational interference, data misappropriation, legal claims, and reputational damage.
• The market for common stock may be limited for U.S. holders due to the heightened risk profile associated with cannabis.
• Possible issuances of capital stock (common or preferred) would cause dilution to existing stockholders.
• The exercise or conversion of outstanding warrants and options into common stock will dilute the percentage ownership of other stockholders.
• The market price of common stock has been historically volatile and could continue to be volatile.
• As an emerging growth company, reduced disclosure requirements could make common stock less attractive to investors.
• Failure to comply with the continued listing standards of the OTCQX tier could result in removal from the marketplace, impacting market value and liquidity.
• Internal controls over financial reporting may not be effective, which could have a significant and adverse effect on the business.

Future Outlook

The company anticipates sales to commence in Pennsylvania and New York in early 2027, following regulatory approvals and construction completion. It continues to monitor regulatory developments closely, particularly regarding federal rescheduling of cannabis and hemp-derived products, to evaluate their potential impact on operations and strategy. Management believes current cash and future funding opportunities will be sufficient to meet anticipated cash needs for working capital and capital expenditures for at least the next twelve months. MariMed also plans to continually assess cybersecurity threats and invest in protective measures.

Management Comments

• "We are a multi-state cannabis operator (MSO) in the United States, headquartered in Norwood, Massachusetts, dedicated to improving lives every day through our high-quality products, our actions, and our values."
• "We believe owning brands that are among the most successful and accessible in the country is critical to our long-term growth."
• "We believe the strength of our brand portfolio has been recognized as a key differentiator from other MSOs."
• "We believe that operating as a vertically integrated cannabis company... provides us the greatest opportunity to maximize revenue and profits."
• "We believe that our strengths in the following areas provide us with certain competitive advantages and the tools necessary to successfully implement our strategic plans."
• "Our management team is one of the most experienced and longest tenured in the cannabis industry."
• "We believe our current cash and future funding opportunities will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for at least the next twelve months."

Industry Context

StockSavvy.ai notes that MariMed operates in a highly dynamic and federally illegal U.S. cannabis market, characterized by rapid state-level legalization and evolving regulatory frameworks. The company's focus on vertical integration and proprietary brands aligns with a common strategy among MSOs to control supply chains and capture market share in a fragmented industry. The ongoing federal rescheduling debate (from Schedule I to Schedule III) is a critical industry-wide catalyst, with potential significant positive impacts like the elimination of Section 280E tax burdens and increased consumer trust, which could benefit all compliant operators like MariMed. However, the emergence of unregulated hemp-derived products poses a competitive threat to the state-regulated market, a challenge faced by many MSOs.

Comparison to Industry Standards

• MariMed's gross margin of 36.2% in 2025 is lower than some leading MSOs, which often report gross margins in the 40-50% range, indicating potential pressure on pricing or higher cost of goods sold. For example, Trulieve Cannabis Corp. (TRUL) and Curaleaf Holdings (CURA) have historically maintained higher gross margins.
• The decline in Adjusted EBITDA from $19.3 million to $16.9 million, alongside increased net loss, suggests operational challenges or increased investment costs compared to peers who might be showing stronger profitability trends in maturing markets.
• The company's strategy of expanding its retail footprint and brand distribution is standard for MSOs, aiming to replicate the success of companies like Green Thumb Industries (GTII) or Cresco Labs (CRLBF) in establishing strong regional presences.
• The $0.7 million loss from a cybersecurity incident highlights a vulnerability that is increasingly common across industries, including cannabis, where robust digital infrastructure and security are crucial for protecting sensitive data and financial transactions.

Corporate Governance

Legal Proceedings

• No material change to previously reported legal proceedings.
• The company may become involved in litigation or regulatory proceedings in the ordinary course of business, with substantial risk of liability in the highly regulated cannabis industry.
• There has been an increasing incidence of class action suits involving the cannabis industry, generally seeking substantial damages.
• The company faces claims and threatened claims from former employees alleging wrongful termination and other similar alleged wrongdoing, which are disputed and not material.
• Settled a bankruptcy claim with GenCanna Global Inc. in 2023, reducing MariMed Hemp, Inc.'s general unsecured claim to $15.5 million, and received final liquidation distributions of $116,250 in 2024 and $50,281 in 2025.
• The IRS filed liens against MariMed for approximately $6 million (June 2025) and its subsidiary FSC for $1.3 million (December 2025) related to 2023 income taxes, which the company is disputing through Collection Due Process Hearings.

Related Party Transactions

• Corporate offices are leased from an entity in which the CEO has an investment interest, with expenses of approximately $285,000 in 2025 and $233,000 in 2024.
• Purchases of nutrients, lab equipment, cultivation supplies, furniture, and tools from an entity owned by the COO's family totaled $6.2 million in 2025 and $4.6 million in 2024.
• Royalties on the Bettys Eddies product line are paid to an entity owned by the COO and CCO, totaling approximately $649,000 in 2025 and $634,000 in 2024.
• Distributions from a majority-owned subsidiary to the CEO (minority equity interest) were approximately $9,000 in 2025 and $6,750 in 2024.
• Distributions from a majority-owned subsidiary to the COO were approximately $27,000 in 2025 and $20,250 in 2024.
• Outstanding accounts payable of approximately $448,000 in 2025 and $251,000 in 2024 were primarily for fixed assets purchased from a third-party company in which the CEO has a controlling interest.
• Assumed approximately $35,000 of accounts payable to a CEO-controlled company as part of the FSC Acquisition.
• Assumed an accounts payable amount of $21,000 from FSC to a second company in which the CEO has a controlling interest.
• The CEO advanced $50,000 to the company in the fourth quarter of 2025 for certain operating activities.
• The company's mortgages with Bank of New England and DuQuoin State Bank are personally guaranteed by the CEO.
• An accrued liability of $2.0 million for electrical work performed at New Bedford and Middleborough properties between 2017 and 2023, performed by an entity owned/controlled by the family of a non-officer/director stockholder, remains on the balance sheet with payment terms under discussion.

Stakeholder Impact

• Shareholders face potential dilution from future issuances of common or preferred stock, as well as the exercise/conversion of outstanding warrants and options. The increased net loss and decreased Adjusted EBITDA could negatively impact stock performance.
• Employees have seen increased headcount due to acquisitions and expansion, but also experienced cost reductions through strategic position elimination and consolidation. Retention of key personnel remains critical for business objectives.
• Customers benefit from the company's focus on an enhanced shopping experience, product selection, and customer loyalty programs. However, product recalls or negative public perception of cannabis could impact demand.
• Suppliers are subject to negotiations for cost reductions on ingredients, nutrients, and packaging. Related party transactions with certain suppliers are notable.
• Creditors are impacted by the company's substantial debt obligations, including the $58.7 million CREM Loan and other mortgages/notes payable. Compliance with loan covenants and the resolution of federal tax liens are important for debt servicing and liquidity.

Next Steps

• Continue executing the "Expand the Brand" strategic growth plan, focusing on strengthening cultivation and processing capabilities.
• Develop and launch innovative new products and broaden the distribution network in existing markets.
• Expand distribution into new markets through new license applications, acquisitions, and/or licensing partners.
• Drive additional and higher average transactions in existing stores through an enhanced customer experience.
• Monitor regulatory developments closely, especially regarding federal rescheduling of cannabis and potential restrictions on hemp-derived products.
• Continue to dispute federal tax liens and negotiate collection alternatives with the IRS.
• Complete the expansion of the Hagerstown, Maryland cultivation facility.
• Anticipate commencement of product sales in Pennsylvania and New York in early 2027.
• Continually assess cybersecurity threats and make investments to increase internal protection, detection, and response capabilities.

Key Dates

Recommendation

MariMed's 2025 performance shows modest revenue growth driven by wholesale, but a concerning decline in gross profit, gross margin, and Adjusted EBITDA, alongside an increased net loss. While strategic acquisitions and market expansions in Delaware and Ohio offer future potential, significant headwinds remain, including federal illegality, the punitive Section 280E tax, and substantial tax liens. The recent Series B debt restructuring alleviates a near-term obligation but highlights ongoing capital management challenges. Given the mixed financial results, the inherent regulatory risks of the cannabis industry, and the ongoing tax disputes, a "hold" recommendation is appropriate. Investors should monitor progress on federal rescheduling, resolution of tax liens, and the company's ability to improve profitability and cash flow from its expanded operations.

Keywords

Cannabis, MSO, Multi-State Operator, MariMed, MRMD, SEC 10-K, Annual Report, Financial Results, Wholesale Cannabis, Retail Cannabis, Adult-Use Cannabis, Medical Cannabis, Cultivation, Processing, Dispensary, Brand Portfolio, Betty's Eddies, Nature's Heritage, Thrive, Acquisitions, Delaware, Illinois, Maryland, Massachusetts, Ohio, Regulatory Risk, Federal Illegality, Section 280E, Tax Lien, Cybersecurity, Capital Structure, Preferred Stock, Debt Restructuring